Axplora’s Strategic Partnerships Cut ADC Payload Timelines and Expand HPAPI Capacity
- Axplora estimates its exatecan production can shave six to nine months off ADC payload development cycles.
- The company will add a new technical building at its Gropello site early next year, creating the largest highly potent API capacity in Europe.
- Axplora emphasizes long‑term, transparent partnerships to align investment decisions with customer pipeline forecasts.
Operational Impact
The upcoming Gropello expansion will boost European HPAPI manufacturing capacity, giving sponsors faster access to potent API slots.
Source: PharmaSource RSS